Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.“

• Jim Abraham,
• Chadi Nabhan,
• Matthew Oberley,
• Wolfgang Michael Korn,
• David Spetzler

Affiliations

Jim Abraham

Caris Life Sciences, Phoenix, AZ; Arizona State University, Phoenix, AZ

Chadi Nabhan

Caris Life Sciences, Phoenix, AZ; University of South Carolina, Department of Clinical Pharmacy and Outcomes Sciences, Columbia, SC

Matthew Oberley

Caris Life Sciences, Phoenix, AZ

Wolfgang Michael Korn

Caris Life Sciences, Phoenix, AZ; University of California in San Francisco, Division of Hematology and Oncology, San Francisco, CA

David Spetzler

Caris Life Sciences, Phoenix, AZ; Arizona State University, Phoenix, AZ; Corresponding author: Research & Development, Caris Life Sciences, 4610 South 44th Place, Phoenix, AZ 85040, USA Phone: 602-464-7537.